Funder: METAvivor
Due Dates (Anticipated): March 2026 (Letter of Intent) | August 2026 (Invited full application & internal submission) | December 2026 (Funding decision)
Funding Amounts: Up to $450,000 total over 3 years; max $150,000/year including up to 5% indirect costs.
Summary: Supports advanced translational and clinical research to improve outcomes for people living with metastatic (stage IV) breast cancer, with required patient advocate involvement.
Key Information: Patient advocate engagement is mandatory in both planning and execution; research must focus on established metastases.